Providing IPS-based Platforms for Pharma & Research Institutions

Providing IPS-based Platforms for Pharmaceutical & Research Institutions

  • High-Volume Manufacturing

    We produce cells with
    consistency on the order
    of billions per lot

  • Expansion


    We expand human
    iPS cells from
    millions to billions

  • Differentiation


    We make iPS-derived
    human cardiac and neuronal cells

  • Shaping


    We shape cells
    into biologically
    relevant microOrgans®

  • Plating


    We provide bulk cells
    or as pre-plated
    assays for high throughput screening



Cells

StemoniX® manufactures human cardiac and neuronal cells for drug toxicity and efficacy testing
  • iPS Cells

    Human induced pluripotent stem cells  Request Info >

  • Cardiac Cells

    Physiologically accurate cardiac cells  Request Info >

  • Neuronal Cells

    Glutamatergic and GABAergic neurons and astrocytes  Request Info >




Drug Screening Plates

StemoniX® can put any individual on a plate
  • microHeart®

    Passively self-aligned cardiac cells to match native human heart tissue structure   Request Info >

  • microBrain®

    Functional neuronal circuity available in standard and MEA microplate formats  Request Info >





The simple things make a difference in how we help you

Human
Human induced pluripotent stem cells (hiPSC) and hiPSC-derived organ cells


Bio-Relevant
We structure and accelerate biology through passive technologies

Economical
Our automation and passive technologies enable us to be the low cost leader

Ready-to-Use
Our screening plates arrive ready-to-use with minimal need for culturing cells


Ambient Shipping
Our plates can be shipped globally at ambient conditions

Consistent
We’ve developed fully automated, high volume manufacturing processes that enable consistent lots of up to 1 billion cells




Miniaturizing, commercializing and personalizing stem cells

StemoniX® makes ready-to-use high-throughput screening plates designed with human microHearts® and microBrains® for drug discovery and development. This effort is revolutionizing stem cell-based research and drug screening, leading to a new era of drug discovery and personalized medicine.



Why StemoniX?

We grow, differentiate, and print organ cells from skin cells, in a way that makes them biologically accurate, to better predict their toxicity and improve efficacy.

infoicon
Blue: DNA staining of fibroblasts highlighting their nuclei

Red: Phalloidin staining of Actin Cytoskeleton

Our technology includes the ability to create a variety of organ cells that can mimic diseases to help accelerate the discovery of new cures in the areas of heart disease, dementia and neuromuscular diseases.

Why StemoniX?

About Us

Our team and scientific board have vetted StemoniX IP with over $200M and a track record of success

30+
Patents
30+
Patents
Pending
Co-founded
9
successful
companies
Authored
7
books

Meet the StemoniX Team

MS, MBA, PMP, PgMP, Ping has formed and led teams to producing world-changing devices. His expertise focuses on merging core intellectual property from startups to F100 corporations.
Ping Yeh | Founder & CEO
Dr. Bob Petcavich, Cofounder & Chief Science Advisor of StemoniX, is a successful serial inventor and entrepreneur, holding nearly 60 patents.
Robert Petcavich | Co-founder
PhD in cell-based assays for high throughput cancer drug discovery. A leader at the Dept. of Medicine & Division of Cardiology at University of California, San Diego.
Fabian Zanella | Head of Cell Biology
MD MBA FACEP, Dr. Khaleghi has led the personalized medicine process for WellnessFX as their medical director. He has also served as CMIO of the Noble Health System, and published 6 health books.
Murdoc Khaleghi | Chief Medical Officer

StemoniX Connections:

What are you interested in?   

Please leave this field empty.